SEC Form 4 · accession 0001140361-16-085049
Protea Biosciences Group, Inc. · PRGB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen C Turner
Officer — Chief Executive Officer · Director
Period of report
Nov 3, 2016
Accepted (ET)
Nov 7, 2016 · 2:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001335103
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 3, 2016 | A | 533,333 | $0.075 | A | 533,333 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Warrant to Purchase Common StockF1 | $0.09 | Nov 3, 2016 | P | 533,333 | A | Nov 3, 2016 | May 3, 2017 | Common Stock | 533,333 | 533,333 | I |
| Class B Warrant to Purchase Common StockF1 | $0.1125 | Nov 3, 2016 | A | 533,333 | A | Nov 3, 2016 | Nov 3, 2021 | Common Stock | 533,333 | 533,333 | I |
Explanation of responses
- F1The spouse of Reporting Person purchased 4 Units of the Issuer's securities for an aggregate purchase price of $40,000, each Unit consisting of (a) 133,333.33 shares of common stock, par value $0.0001 per share (the "Common Stock"), (b) 18 month warrants to purchase up to 133,333.33 shares of Common Stock at an exercise price of $0.09 per share (the "Class A Warrants"), and (c) five year warrants to purchase up to 133,333.33 shares of Common Stock at an exercise price of $0.1125 per share (the "Class B Warrants").